Upon completion of his PhD degree in Biophysical Chemistry at California Institute of Technology in 1972, he joined Dr. Nathan Kaplan’s lab at UCSD as NIH Postdoctoral Fellow to carry out pioneer work on general ligand affinity chromatography. In 1976, he joined National Institutes of Health as senior fellow to study enzymology and biochemical genetics. In 1981, he was appointed as faculty member and director of Andrology Laboratory at The University of British Columbia. During the last two decades, he has created numerous monoclonal antibodies for diagnostic and therapeutic applications in human health care. Among these, RP215 and GHR106 monoclonal antibodies have recently been discovered to be promising candidates of multi-indication anti-cancer drugs for the therapeutic treatments of various human cancers in the future.
Research and Development of Antibody-Based Anti-Cancer Drugs
- RP215 monoclonal antibody was shown to recognize specifically a carbohydrate-associated epitope located on the variable regions of cancer cell expressed immunoglobulin superfamily proteins, designated in general as CA215.
- Structural elucidation of carbohydrate-associated epitope in CA215 which is recognized by RP215 monoclonal antibody (Mab)
- Humanizations of RP215 Mab for preclinical studies
- Generations of Rat anti-idiotype Mabs as candidates for the development of anti-cancer vaccines in humans
- Establishment of an Anti-GnRH receptor Mab, GHR106, as a substitute of short-acting GnRH analogs for antibody-based anti-cancer drugs, as well as preclinical studies.
- Elucidation of mechanisms of action for RP215 and GHR106 as antibody-based anti-cancer drugs.
- Elucidation of a carbohydrate-associated epitope recognized by RP215 monoclonal antibody.
- Cancer biology & therapy - 2009, Jan 22
- Cancer biology & therapy - 2009, Mar 2
- Cancer biomarkers : section A of Disease markers - 2009, May 1
- Cancer biomarkers : section A of Disease markers - 2009, Sep 4
- Cancer immunology, immunotherapy : CII - 2010, Apr 28